Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
Coates LC., Landewé R., McInnes IB., Mease PJ., Ritchlin CT., Tanaka Y., Asahina A., Behrens F., Gladman DD., Gossec L., Orbai A-M., Gottlieb AB., Warren RB., Ink B., Bajracharya R., Shende V., Coarse J., Merola JF.